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Time to Recognise HIV Infection as an important risk factor of stroke in Sub-Saharan 
Africa? 
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When it comes to making a case for the growing burden of stroke in Low-to-Middle income 
countries (LMICs), specifically in sub-Saharan Africa, HIV infection has consistently been 
neglected.  We read with interest The Lancet series on Stroke systems of care and 
rehabilitation in LMICs,  but were disappointed to see HIV overlooked here too.1,2  According 
to statistics from the World Health Organization, about 36.7 million people are currently living 
with HIV, and 1.8 million become infected every year. Antiretroviral therapy (ART) has 
successfully limited AIDS related complications but has transformed HIV infection to a chronic 
disease with important complications. HIV is disproportionately concentrated in sub-Saharan 
Africa, where 71% of the total global burden is found.  
  
The most compelling evidence to link HIV and cardiovascular disease is from a meta-analysis 
which showed the population-attributable fraction (PAF), increasing globally from 0.36% (95% 
CI, 0.21%–0.56%) in 1990 to 0.92% (95% CI, 0.55%–1.41%) in 20153. In Sub-Saharan Africa  
the PAF was as high as 30%. This was associated with a more than 3-fold increase in Disability 
Adjusted Life Years from HIV-associated cardiovascular disease. These figures have almost 
tripled in two decades, and occurred despite antiretroviral therapy. In Malawi, we have shown 
the PAF of HIV-related stroke to be 15% and identified that HIV infection was now the second 
leading risk factor for stroke.4 
  
We are encouraged that the spotlight for stroke care and rehabilitation is now focusing on Sub-
Saharan Africa, however paying insufficient attention to HIV infection could limit progress. 
Stroke management is different in the context of HIV, and a multi-morbidity approach is 
needed. For example, there is an extended and mostly treatable list of causes of stroke in HIV 
which may not be considered if a patient’s HIV status is not known.5 HIV patients with stroke 
patients can also suffer from the dual burden of two stigmatising diseases which may influence 
their access to care. Additionally, there are complex drug interactions to consider. To 
comprehensively design effective stroke care and rehabilitation pathways in HIV endemic 
regions, we must include HIV on the agenda. In 2019 The American Heart and Stroke 
Association, for the first time, wrote a scientific statement on HIV infection and cardiovascular 
disease, setting the tone for urgent action.5 We urge clinicians and policymakers involved in 
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